Robert Brooke

Robert (Bobby) Brooke is a bioengineer and biotech entrepreneur whose work is focused on aging & longevity.   

He is the co-founder of the non-profit Epigenetic Clock Development Foundation (Clock Foundation; www.clockfoundation.org) with Dr. Steve Horvath from UCLA.  The Clock Foundation is dedicated to enabling rigorous and widespread use of epigenetic clocks and other key aging biomarkers, especially for use in testing new longevity interventions.  In the foundation’s first 3 years of operations, it has completed more than 300 collaborative projects, including testing for human clinical trials, canine & rodent studies, and for species with exceptional longevity such as naked mole rats and bowhead whales.  These studies have also focused on assessment of emerging longevity treatments including plasmapheresis, T cell rejuvenation, and epigenetic reprogramming.   

Mr. Brooke is also the CEO and CTO of Intervene Immune (www.interveneimmune.com), a private biotechnology startup located in Los Angeles that is developing treatments to enable thymus regeneration.  The company is using a drug cocktail of agents that have already been FDA approved to help slow or prevent normal age-related immune system decline.  Intervene conducted a pilot clinical study at Stanford University known as the TRIIM trial that documented the first significant reversal of epigenetic aging.  It is now conducting the larger TRIIM-X trial, enrolling men and women age 40-80 from across the U.S., and is headquartered at the Harbor-UCLA Medical Center in Torrance, CA.   

Mr. Brooke previously founded a cancer immunotherapy company, which is now known as Iovance Biotherapeutics (NASDAQ: IOVA).  It is currently focused on harnessing the body’s immune system to fight cancer through development of TIL therapies.  He also previously was a healthcare and life sciences investment analyst.   

He earned a B.S. in Electrical Engineering from Georgia Tech in 2003 and a M.S. in Biomedical Engineering from UCLA in 2005.